Leveraging drug conjugate technology to selectively deliver medicine to regenerate bone
Latest News
12.15.20
Webinar on Duchenne muscular dystrophy bone health is now available online
11.17.20
David C. Dvorak joins Mesentech's Board of Directors
11.17.20
Barbara Yanni joins Mesentech's Board of Directors
11.10.20
CureDuchenne Ventures, and Charles H. Hood Foundation invest in Mesentech for development of Novel Duchenne Muscular Dystrophy Therapy
